BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms BARIOPTIMISE
- 04 Oct 2020 Status changed from active, no longer recruiting to completed.
- 27 Mar 2020 Planned End Date changed from 1 Nov 2019 to 1 Jun 2020.
- 27 Mar 2020 Status changed from recruiting to active, no longer recruiting.